StockpollyBeta
Get App
Popularity #4,429
ALGS · NASDAQ · Biotechnology

Aligos Therapeutics (ALGS)

Develops liver- and viral-disease drug candidates, including a chronic hepatitis B program.

$6.00
vs last close+0.51 (+9.22%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue3311110110328
Cost of revenue000100000000
Gross profit3310110110328
222923272121201929223030
Research & development162216211716151424172324
667655565566
Selling & marketing000−100000000
General & administrative667655565066
Other expenses000000000000
Operating income−19−26−22−26−20−21−19−19−28−22−27−2
1−2−13321−62623−3243
Interest income121000100110
Other non-operating income0213−32−162−62−33−2−4−3
Income before tax−18−28−355−19−8243−16−31−20−231
Income tax expense000000000003
Net income from continuing operations−18−28−355−19−8243−16−32−20−23−2
Net income−18−28−355−19−8243−16−32−20−23−2
EPS, basic−$0.41−$1.12−$2.24$0.81−$3.07−$13.08$5.12−$1.53−$3.04−$1.91−$2.21−$0.14
EPS, diluted−$0.41−$1.12−$2.24$0.81−$3.07−$13.08$4.95−$1.53−$3.04−$1.91−$2.21−$0.14
Weighted average shares, basic43251666681010101010
Weighted average shares, diluted43251666691010101010
EBITDA−18−27−346−19−8144−15−31−20−222
Depreciation & amortization111111101000
EBIT−19−28−355−19−8243−16−31−20−231